Role of prucalopride, a serotonin (5-HT₄) receptor agonist, for the treatment of chronic constipation

References

• ChoungRSLockeGR3rdSchleckCDZinsmeisterARTalleyNJCumulative incidence of chronic constipation: a population-based study 1988–2003Aliment Pharmacol Ther2007261521152817919271
   PubMed Web of Science ®Google Scholar
• DrossmanDAThe functional gastrointestinal disorders and the Rome III processGastroenterology20061301377139016678553
   PubMed Web of Science ®Google Scholar
• DennisonCPrasadMLloydABhattacharyyaSKDhawanRCoyneKThe health-related quality of life and economic burden of constipationPharmacoeconomics20052346147615896098
   PubMed Web of Science ®Google Scholar
• StewartWFLibermanJNSandlerRSEpidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic featuresAm J Gastroenterol1999943530354010606315
   PubMed Web of Science ®Google Scholar
• HigginsPDJohansonJFEpidemiology of constipation in North America: a systematic reviewAm J Gastroenterol20049975075915089911
   PubMed Web of Science ®Google Scholar
• SonnenbergAKochTRPhysician visits in the United States for constipation: 1958 to 1986Dig Dis Sci1989346066112784759
   PubMed Web of Science ®Google Scholar
• IrvineEJFerrazziSParePThompsonWGRanceLHealth-related quality of life in functional GI disorders: focus on constipation and resource utilizationAm J Gastroenterol2002971986199312190165
   PubMed Web of Science ®Google Scholar
• JohansonJFKralsteinJChronic constipation: a survey of the patient perspectiveAliment Pharmacol Ther20072559960817305761
   PubMed Web of Science ®Google Scholar
• JohansonJFReview of the treatment options for chronic constipationMed Gen Med2007925
   PubMedGoogle Scholar
• LemboACamilleriMChronic constipationN Engl J Med20033491360136814523145
   PubMed Web of Science ®Google Scholar
• MeshkinpourHSelodSMovahediHNamiNJamesNWilsonAEffects of regular exercise in management of chronic idiopathic constipationDig Dis Sci199843237923839824122
   PubMed Web of Science ®Google Scholar
• YoungRJBeermanLEVanderhoofJAIncreasing oral fluids in chronic constipation in childrenGastroenterol Nurs1998211561619849179
   PubMedGoogle Scholar
• JohansonJFMortonDGeenenJUenoRMulticenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipationAm J Gastroenterol200810317017717916109
   PubMed Web of Science ®Google Scholar
• SweetserSBusciglioIACamilleriMEffect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjectsAm J Physiol Gastrointest Liver Physiol2009296G295G30119033530
   PubMed Web of Science ®Google Scholar
• FinkSChaudhuriTKPalmerJDCisapride accelerates colonic transit in constipated patients with colonic inertiaAm J Gastroenterol1990852162172301347
   PubMed Web of Science ®Google Scholar
• PratherCMCamilleriMZinsmeisterARMcKinzieSThomfordeGTegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndromeGastroenterology200011846346810702196
   PubMed Web of Science ®Google Scholar
• TackJMuller-LissnerSBytzerPA randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipationGut2005541707171316020489
   PubMed Web of Science ®Google Scholar
• De MaeyerJHLefebvreRASchuurkesJA5-HT4 receptor agonists: similar but not the sameNeurogastroenterol Motil2008209911218199093
   PubMed Web of Science ®Google Scholar
• WysowskiDKCorkenAGallo-TorresHTalaricoLRodriguezEMPostmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actionsAm J Gastroenterol2001961698170311419817
   PubMed Web of Science ®Google Scholar
• JonesMPTalleyNJNuytsGDuboisDLack of objective evidence of efficacy of laxatives in chronic constipationDig Dis Sci2002472222223012395895
   PubMed Web of Science ®Google Scholar
• PetticrewMRodgersMBoothAEffectiveness of laxatives in adultsQual Health Care20011026827311743157
   PubMedGoogle Scholar
• TramonteSMBrandMBMulrowCDAmatoMGO’KeefeMERamirezGThe treatment of chronic constipation in adults. A systematic reviewJ Gen Intern Med19971215249034942
   PubMed Web of Science ®Google Scholar
• AndresenVCamilleriMBusciglioIAEffect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndromeGastroenterology200713376176817854590
   PubMed Web of Science ®Google Scholar
• LemboAJKurtzCBMacdougallJELinaclotide is effective for patients with chronic constipationGastroenterology2009
   Google Scholar
• CoulieBSzarkaLACamilleriMRecombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humansGastroenterology2000119415010889153
   PubMed Web of Science ®Google Scholar
• ParkmanHPRaoSSReynoldsJCNeurotrophin-3 improves functional constipationAm J Gastroenterol2003981338134712818279
   PubMed Web of Science ®Google Scholar
• BriejerMRBosmansJPVan DaelePThe in vitro pharmacological profile of prucalopride, a novel enterokinetic compoundEur J Pharmacol2001423718311438309
   PubMed Web of Science ®Google Scholar
• HegdeSSEglenRMPeripheral 5-HT4 receptorsFaseb J199610139814078903510
   PubMed Web of Science ®Google Scholar
• PrinsNHAkkermansLMLefebvreRASchuurkesJA5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscleBr J Pharmacol200013192793211053213
   PubMed Web of Science ®Google Scholar
• PrinsNHVan HaselenJFLefebvreRABriejerMRAkkermansLMSchuurkesJAPharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscleBr J Pharmacol19991271431143710455293
   PubMed Web of Science ®Google Scholar
• BriejerMRPrinsNHSchuurkesJAEffects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogsNeurogastroenterol Motil20011346547211696108
   PubMed Web of Science ®Google Scholar
• BassottiGChiarioniGVantiniIAnorectal manometric abnormalities and colonic propulsive impairment in patients with severe chronic idiopathic constipationDig Dis Sci199439155815648026270
   PubMed Web of Science ®Google Scholar
• QiHBLuoJYLiuXEffect of enterokinetic prucalopride on intestinal motility in fast ratsWorld J Gastroenterol200392065206712970907
   PubMed Web of Science ®Google Scholar
• PrinsNHvan Der GrijnALefebvreRAAkkermansLMSchuurkesJA5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo studyBr J Pharmacol20011321941194711309267
   PubMed Web of Science ®Google Scholar
• BriejerMMeulemansAWellensASchuurkensJR093877 dose-dependently accelerates gastric emptying in conscious dogsGastroenterology1997112A705
   Web of Science ®Google Scholar
• Van de VeldeVAusmaJVandeplasscheLPharmacokinetics of prucalopride (Resolor®) in manGut200857A282
   Google Scholar
• Investigator’s brochure on prucalopride. Movetis NV, Turnhout, Belgium.
   Google Scholar
• BourasEPCamilleriMBurtonDDMcKinzieSSelective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humansGut19994468268610205205
   PubMed Web of Science ®Google Scholar
• PoenACFelt-BersmaRJVan DongenPAMeuwissenSGEffect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteersAliment Pharmacol Ther1999131493149710571606
   PubMed Web of Science ®Google Scholar
• EmmanuelAVKammMARoyAJAntonelliKEffect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteersGut1998425115169616313
   PubMed Web of Science ®Google Scholar
• De SchryverAMAndriesseGISamsomMSmoutAJGooszenHGAkkermansLMThe effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteersAliment Pharmacol Ther20021660361211876716
   PubMed Web of Science ®Google Scholar
• BourasEPCamilleriMBurtonDDThomfordeGMcKinzieSZinsmeisterARPrucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorderGastroenterology200112035436011159875
   PubMed Web of Science ®Google Scholar
• EmmanuelAVRoyAJNichollsTJKammMAPrucalopride, a systemic enterokinetic, for the treatment of constipationAliment Pharmacol Ther2002161347135612144586
   PubMed Web of Science ®Google Scholar
• SlootsCEPoenACKerstensREffects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipationAliment Pharmacol Ther20021675976711929394
   PubMed Web of Science ®Google Scholar
• CoremansGKerstensRDe PauwMStevensMPrucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trialDigestion200367828912743445
   PubMed Web of Science ®Google Scholar
• NicholsTBeyensGAusmaJA double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of prucalopride in patients with chronic constipation UEGW. Vienna2008P0894
   Google Scholar
• MinerPJNicholsTSilversDThe efficacy and safety of prucalopride in patients with chronic constipationGastroenterology1999116A1043
   PubMed Web of Science ®Google Scholar
• Felt-BersmaRBouchouchaMWurzerHEffects of a new enterokinetic drug, prucalopride, on symptoms of patients with chronic constipation: a double-blind, placebo-controlled, multicenter study in EuropeGastroenterology1999116A1043
   PubMed Web of Science ®Google Scholar
• EmmanuelAVRoyAJNichollsTJKammMAPrucalopride, a systemic enterokinetic, for the treatment of constipationAliment Pharmacol Ther2002161347135612144586
   PubMed Web of Science ®Google Scholar
• WinterHAusmaJVandeplasscheLAn open label follow-up study of prucalopride solution in pediatric subjects with functional fecal retentionGastroenterology2009136A129
   Web of Science ®Google Scholar
• MoulinDRykxAKerstensRVandeplasscheLRandomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor®) in patients with opioid-induced constipationGastroenterology2008134A92
   Google Scholar
• KroghKJensenMBGandrupPEfficacy and tolerability of prucalopride in patients with constipation due to spinal cord injuryScand J Gastroenterol20023743143611989834
   PubMed Web of Science ®Google Scholar
• D’HoogheBGuillaumDMedaerRTreatment of constipation in multiple sclerosis patients: pilot study with the novel enterokinetic prucaloprideNeurogastroenterol Motil199911A256
   Google Scholar
• CamilleriMKerstensRRykxAVandeplasscheLA placebo-controlled trial of prucalopride for severe chronic constipationN Engl J Med20083582344235418509121
   PubMed Web of Science ®Google Scholar
• QuigleyEMVandeplasscheLKerstensRAusmaJClinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled studyAliment Pharmacol Ther20092931532819035970
   PubMed Web of Science ®Google Scholar
• TackJvan OutryveMBeyensGPrucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxativesGut20095835736518987031
   PubMed Web of Science ®Google Scholar
• FrankLKleinmanLFarupCPsychometric validation of a constipation symptom assessment questionnaireScand J Gastroenterol19993487087710522604
   PubMed Web of Science ®Google Scholar
• MarquisPDe La LogeCDuboisDDevelopment and validation of the Patient Assessment of Constipation Quality of Life questionnaireScand J Gastroenterol20054054055116036506
   PubMed Web of Science ®Google Scholar
• GalandiukSRykxAAusmaJA two-period, double-blind, placebo-controlled study to evaluate the effects of re-treatment of prucalopride (Resolor) on efficacy and safety in patients with chronic constipationGut200857Suppl IIA86
   Google Scholar
• JohansonJFWaldATougasGEffect of tegaserod in chronic constipation: a randomized, double-blind, controlled trialClin Gastroenterol Hepatol2004279680515354280
   PubMed Web of Science ®Google Scholar
• TackJMiddletonSHorneMPilot study of the efficacy of renzapride on GI motility and symptoms in patients with constipation-predominant irritable bowel syndromeAliment Pharmacol Ther2006231655166516696817
   PubMed Web of Science ®Google Scholar
• Müller-LissnerSTreatment of chronic constipation with cisapride and placeboGut198728103310383311905
   PubMed Web of Science ®Google Scholar
• PetticrewMRodgersMBoothAEffectiveness of laxatives in adultsQual Health Care20011026827311743157
   PubMedGoogle Scholar
• CamilleriMBeyensGKerstensRVandeplasscheLLong-term follow-up safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipationGastroenterology2009136A31
   Web of Science ®Google Scholar
• Van OutryveMJBeyensGKerstensRLong term follow-up study of oral prucalopride (Resolor) administered to patients with chronic constipation [abstract #T1400]Gastroenterology20081344 Suppl 1A547
   Web of Science ®Google Scholar
• Propulsid (cisapride) Dear Healthcare Professional Letter. FDA, Safety Information. Washington DC: FDA/Safety, 2000. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175000.htm Accessed Sep 27, 2009
   Google Scholar
• KrobertKABrattelidTLevyFOKaumannAJPrucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variantsNaunyn Schmiedebergs Arch Pharmacol200537147347916012870
   PubMed Web of Science ®Google Scholar
• De MaeyerJStraetemansRSchuurkesJLefebvreRPorcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of developmentBr J Pharmacol200614714015716331294
   PubMed Web of Science ®Google Scholar
• BachTSyversveenTKvingedalA5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricleNaunyn Schmiedebergs Arch Pharmacol200136314616011218067
   PubMed Web of Science ®Google Scholar
• De MaeyerJHSchuurkesJALefebvreRASelective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomachBr J Pharmacol200915636237619154432
   PubMed Web of Science ®Google Scholar
• PotetFBouyssouTEscandeDBaroIGI prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channelJ Pharmacol Exp Ther20012991007101211714889
   PubMed Web of Science ®Google Scholar
• ChapmanHPasternackMThe action of the novel GI prokinetic prucalopride on the HERG K+ channel and the common T897 polymorphEur J Pharmacol20075549810517109852
   PubMed Web of Science ®Google Scholar
• PauDWorkmanAJKaneKARankinACElectrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonistsJ Pharmacol Exp Ther200531314615315644433
   PubMed Web of Science ®Google Scholar
• BoyceMKerstensRBeyensGCardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trailsGastroenterology2009136T1265
   Google Scholar
• CamilleriMBeyensGKerstensRSafety assessment of prucalopride in elderly patients with constipation: a double-blind, placebocontrolled studyNeurogastroenterol Motil Epub200999
   Web of Science ®Google Scholar
• BourasEPCamilleriMBurtonDDPrucalopride accelerates GI and colonic transit in patients with constipation without a rectal evacuation disorderGastroenterology200112035436011159875
   PubMed Web of Science ®Google Scholar
• SlootsCEPoenACKerstensREffects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipationAliment Pharmacol Ther20021675976711929394
   PubMed Web of Science ®Google Scholar
• Committee for medicinal products for human use: summary of positive opinion for Resolor. EMEA Committee for medicinal products for human use. London: EMEA/Pre-Authorisation Evaluation of Medicines for Human Use, 2009. Available at: http://www.emea.europa.eu/pdfs/human/opinion/Resolor_44905009en.pdf Accessed Sep 27, 2009.
   Google Scholar
• CamilleriMDeiterenAInvited Review. Prucalopride for constipationExp Opin Pharmacother201011451461
   PubMed Web of Science ®Google Scholar